Literature DB >> 6682964

The measurement of Ascaris suum protein by radioimmunoassay in sera from patients with helminthiasis and with gastrointestinal diseases.

K Tanaka, H Kawamura, N Tohgi, M Tsuji, Y Miyachi, A Miyoshi.   

Abstract

In this study, we have developed a reliable radioimmunoassay (RIA) for Ascaris suum protein (Asp) and have measured the serum concentration of Asp in control subjects and in patients with helminthiasis and a variety of gastrointestinal diseases. The cross-reactivities of Asp antibody with other helminth worm antigens were also measured by RIA. Ascaris lumbricoides contained approximately the same amount of Asp antigenic substance as did Ascaris suum. Toxocara canis had a high concentration of a substance partially cross-reactive with Asp. Small amounts of substance cross-reacting with Asp were also exhibited by Anisakis larvae, Schistosoma japonicum and Taenia saginata. However, no cross-reactivities of Fasciola hepatica and Paragonimus westermani with Asp were observed in this study. Almost all the serum levels of Asp from normal control subjects were below the sensitivity of this RIA (10 ng/ml). High concentrations of Asp were observed in sera from patients with ascariasis (64.5 +/- 18.8 ng/ml: mean +/- S.E.), anisakiasis (75.2 +/- 28.0 ng/ml), toxocariasis (78.4 +/- 31.3 ng/ml) and schistosomiasis japonica (14.3 +/- 3.4 ng/ml). Asp levels in sera from patients with other helminthiasis were not significantly high. From these findings, it was suggested that RIA for Asp may not be specific for diagnosis of ascariasis, but might be a suitable screening method for patients with some kinds of helminthiasis. Interestingly, high concentrations of Asp were also observed in sera from patients with ulcerative colitis (24.8 +/- 2.5 ng/ml) and Crohn's disease (19.8 +/- 5.2 ng/ml), but Asp levels from 7 other gastrointestinal diseases seemed not to be significantly high. These findings remain unexplained but may derive from cross-reactivities between helminthic and gut mucosal antigens.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682964     DOI: 10.1017/s0031182000050459

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  6 in total

1.  Determination of Anti-Anisakis Simplex Antibodies and Relationship with αβ and γδ Lymphocyte Subpopulations in Patients with Crohn's Disease.

Authors:  C Benet-Campos; C Cuéllar; C García-Ballesteros; V Zamora; R Gil-Borrás; I Catalán-Serra; F López-Chuliá; J C Andreu-Ballester
Journal:  Dig Dis Sci       Date:  2017-02-06       Impact factor: 3.199

2.  Evidence for in utero sensitization to Ascaris lumbricoides in newborns of mothers with ascariasis.

Authors:  Irene Guadalupe; Edward Mitre; Susana Benitez; Martha E Chico; Thomas B Nutman; Philip J Cooper
Journal:  J Infect Dis       Date:  2009-06-15       Impact factor: 5.226

Review 3.  The potential impact of early exposures to geohelminth infections on the development of atopy.

Authors:  Philip J Cooper
Journal:  Clin Rev Allergy Immunol       Date:  2004-02       Impact factor: 8.667

4.  Impact of early life geohelminths on wheeze, asthma and atopy in Ecuadorian children at 8 years.

Authors:  Philip J Cooper; Irina Chis Ster; Martha E Chico; Maritza Vaca; Yisela Oviedo; Augusto Maldonado; Mauricio L Barreto; Thomas A E Platts-Mills; David P Strachan
Journal:  Allergy       Date:  2021-04-07       Impact factor: 14.710

5.  Maternal geohelminth infections are associated with an increased susceptibility to geohelminth infection in children: a case-control study.

Authors:  Raaj S Mehta; Alejandro Rodriguez; Martha Chico; Irene Guadalupe; Nely Broncano; Carlos Sandoval; Fernanda Tupiza; Edward Mitre; Philip J Cooper
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24

6.  Risk factors for soil-transmitted helminth infections during the first 3 years of life in the tropics; findings from a birth cohort.

Authors:  Stefanie K Menzies; Alejandro Rodriguez; Martha Chico; Carlos Sandoval; Nely Broncano; Irene Guadalupe; Philip J Cooper
Journal:  PLoS Negl Trop Dis       Date:  2014-02-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.